How have DPK shares performed in 2024?

Direxion Daily MSCI Developed Markets Bear 3X Shares' stock was trading at $15.78 at the beginning of 2024. Since then, DPK shares have decreased by 0.0% and is now trading at $15.7756. View the best growth stocks for 2024 here .

What does DPK invest in?

Direxion Daily MSCI Developed Markets Bear 3X Shares is a equity fund issued by Direxion. DPK focuses on broad equity investments and follows the MSCI EAFE Index. The fund's investments total to approximately $5.30 million assets under management.

What is the management fee for Direxion Daily MSCI Developed Markets Bear 3X Shares?

Direxion Daily MSCI Developed Markets Bear 3X Shares' management fee is 0.75% and has other expenses of 1.66%. However, DPK has a fee waiver of -1.31% to reimburse the expenses. The net expense ratio for DPK is 1.10%.

What other stocks do shareholders of Direxion Daily MSCI Developed Markets Bear 3X Shares own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Direxion Daily MSCI Developed Markets Bear 3X Shares investors own include Coherus BioSciences (CHRS) , ContraFect (CFRX) , CTI BioPharma (CTIC) , Evolus (EOLS) , Fate Therapeutics (FATE) , Galectin Therapeutics (GALT) , Johnson & Johnson (JNJ) , Reata Pharmaceuticals (RETA) , Tonix Pharmaceuticals (TNXP) and TapImmune (TPIV) .

How do I buy shares of Direxion Daily MSCI Developed Markets Bear 3X Shares?

Shares of DPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEARCA:DPK

Direxion Daily MSCI Developed Markets Bear 3X Shares (DPK) Price, Holdings, & News

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free DPK Stock Alerts

$15.78

0.00 (0.00%)

(As of 05/12/2023)

Compare

Today's Range: $15.78
▼
$15.78
50-Day Range: $15.78
▼
$15.78
52-Week Range: $9.48
▼
$26.57

Volume: N/A
Average Volume: 63,040 shs
Market Capitalization: $5.28 million

Assets Under Management: $5.30 million
Dividend Yield: 1.14%
Net Expense Ratio: 1.10%

Stock Analysis

Get Direxion Daily MSCI Developed Markets Bear 3X Shares alerts:

DPK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DPK ETF News Headlines

February 23, 2023 | entrepreneur.com

What Is a Bear Market? Everything You Need To Know.

October 1, 2022 | morningstar.com

Direxion Daily MSCI Em Mkts Bear 3X ETF

See More Headlines

Receive DPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Direxion Daily MSCI Developed Markets Bear 3X Shares and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer: Direxion
Fund Name: Direxion Daily Developed Markets Bear 3X Shares
Tax Classification: Regulated Investment Company
Stock Exchange: NYSEARCA
Current Symbol: NYSEARCA:DPK
Inception Date: 12/16/2008
Fund Manager: Paul Brigandi, Tony Ng
Web: N/A
Phone: 1.866.476.7523

Fund Focus

Asset Class: Equity
Benchmark: MSCI EAFE Index
Category: Broad Equity
Focus: Broad Equity
Development Level: Developed Markets
Region: Developed Markets
Number of Holdings: 0

Fund Statistics

Assets Under Management: $5.30 million
Average Daily Volume: $107,725.60
Discount/Premium: -0.04%

Administrator, Advisor and Custodian

Administrator: U.S. Bancorp Fund Services, LLC
Advisor: Rafferty Asset Management, LLC
Custodian: The Bank of New York Mellon Corporation
Distributor: Foreside Fund Services, LLC
Transfer Agent: The Bank of New York Mellon Corporation
Trustee: N/A
Lead Market Maker: Virtu Financial

Miscellaneous

Outstanding Shares: 335,000
Beta: N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

Direxion Daily MSCI Developed Markets Bear 3X Shares Expenses

Type	DPK	Broad Equity ETFs	Equity ETFs	NYSEARCA ETFs	All ETFs
Management Fee	0.75%	0.52%	0.54%	0.50%	0.51%
Other Expenses	1.66%	0.53%	0.54%	0.64%	0.58%
Total Expense	2.41%	0.77%	0.70%	0.74%	0.70%
Fee Waiver	-1.31%	-0.41%	-0.55%	-0.68%	-0.57%
Net Expense	1.10%	0.62%	0.60%	0.58%	0.58%